HUP0103452A2 - MMP inhibitor hidroxi-pipekolát-hidroxámsav származékok és a vegyületeket tartalmazó gyógyászati készítmények - Google Patents

MMP inhibitor hidroxi-pipekolát-hidroxámsav származékok és a vegyületeket tartalmazó gyógyászati készítmények

Info

Publication number
HUP0103452A2
HUP0103452A2 HU0103452A HUP0103452A HUP0103452A2 HU P0103452 A2 HUP0103452 A2 HU P0103452A2 HU 0103452 A HU0103452 A HU 0103452A HU P0103452 A HUP0103452 A HU P0103452A HU P0103452 A2 HUP0103452 A2 HU P0103452A2
Authority
HU
Hungary
Prior art keywords
alkyl
heteroaryl
aryl
carbon
atom
Prior art date
Application number
HU0103452A
Other languages
English (en)
Inventor
Louis Stanley Chupak
Michael Anthony Letavic
Kim Francis Mcclure
Mark Carl Noe
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HUP0103452A2 publication Critical patent/HUP0103452A2/hu
Publication of HUP0103452A3 publication Critical patent/HUP0103452A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A jelen tal lm ny t rgy t azok az (I) ltal nos képletű vegyületekképezik, ahol a képletben szereplő R1, R2, R3, R4, R5, R6, R7, R8, R9,valamint Ar jelentése az al bbiakban kerül ismertetésre, amelyek azarthritis, a rosszindulatú daganatos betegségek vagy egyéb m trixmetalloprotein z vagy emberi reprolizin aktivit ssal jellemzett egyébbetegség kezelésére alkalmasak. Emellett a jelen tal lm ny szerintivegyületek felhaszn lhatók standard nem szteroid gyullad sellenesgyógyszerekkel (NAID's), COX-2 inhibitorokkal és analgetikumokkalkombin lt ter pi kban és olyan citotoxikus gyógyszerekkel kombin lva,mint az adriamycin, daunomycin, cisz-platinum, etoposid, taxol,taxoter és egyéb olyan alkaloidok, mint a vincristin, a rosszindulatúdaganatos betegségek kezelésében. R1-R8 jelentése a hidroxicsoport,hidrogénatom, halogénatom (előny"sen klór- vagy fluoratom), -CN, 1-6szénatomos alkil, 2-6 szénatomos alkenil, (6-10 szénatomos aril)-(2-6szénatomos alkenil), (2-9 szénatomos heteroaril)-(2-6 szénatomosalkenil), 2-6 szénatomos alkinil, (6-10 szénatomos aril)-(2-6szénatomos alkinil), (2-9 szénatomos heteroaril)-(2-6 szénatomosalkinil), 1-6 szénatomos alkil-amino, 1-6 szénatomos alkiltio, 1-6szénatomos alkoxi, perfluor-(1-6 szénatomos alkil), 6-10 szénatomosaril, 2-9 szénatomos heteroaril, 6-10 szénatomos aril-amino, 6-10szénatomos aril-tio, 6-10 szénatomos ariloxi, 2-9 szénatomosheteroaril-amino, 2-9 szénatomos heteroaril-tio, 2-9 szénatomosheteroaril-oxi, 3-6 szénatomos cikloalkil, (1-6 szénatomos alkil)-(hidroxi-metilén), piperidil, (1-6 szénatomos alkil)-piperidil, 1-6szénatomos acilamino, 1-6 szénatomos acil-tio, 1-6 szénatomos aciloxi,(1-6 szénatomos alkoxi)-(C=O)-, -CO2H, (1-6 szénatomos alkil)-NH-(C=O)- és[(1-6 szénatomos alkil)]2-N-(C=O)-csoport; Ar jelentése (6-10 szénatomos aril)-(1-6 szénatomos alkoxi)-6-10 szénatomos aril), (6-10 szénatomos aril)-(1-6 szénatomos alkoxi)-(2-9 szénatomosheteroaril), (2-9 szénatomos heteroaril)-(1-6 szénatomos alkoxi)-(6-10szénatomos aril), (2-9 szénatomos heteroaril)-(1-6 szénatomos alkoxi)-(2-9 szénatomos heteroaril) csoport, amelyek adott esetben egy vagyt"bb szubsztituenssel helyettesítettek. Ó
HU0103452A 1998-08-12 1999-08-05 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds HUP0103452A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9623298P 1998-08-12 1998-08-12
PCT/IB1999/001388 WO2000009485A1 (en) 1998-08-12 1999-08-05 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors

Publications (2)

Publication Number Publication Date
HUP0103452A2 true HUP0103452A2 (hu) 2002-04-29
HUP0103452A3 HUP0103452A3 (en) 2002-10-28

Family

ID=22256467

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103452A HUP0103452A3 (en) 1998-08-12 1999-08-05 Hydroxy pipecolate hydroxamic acid derivatives as mmp inhibitors and pharmaceutical compositions containing the compounds

Country Status (43)

Country Link
US (2) US6329397B1 (hu)
EP (1) EP1104403B1 (hu)
JP (1) JP2002522528A (hu)
KR (1) KR20010085374A (hu)
CN (1) CN1316995A (hu)
AP (1) AP2001002070A0 (hu)
AR (1) AR019241A1 (hu)
AT (1) ATE325791T1 (hu)
AU (1) AU766366B2 (hu)
BG (1) BG105323A (hu)
BR (1) BR9912909A (hu)
CA (1) CA2340202C (hu)
CZ (1) CZ2001484A3 (hu)
DE (1) DE69931266T2 (hu)
DZ (1) DZ2870A1 (hu)
EA (1) EA200100126A1 (hu)
EE (1) EE200100086A (hu)
ES (1) ES2263279T3 (hu)
GE (1) GEP20033117B (hu)
GT (1) GT199900131A (hu)
HK (1) HK1040242A1 (hu)
HN (1) HN1999000131A (hu)
HR (1) HRP20010098A2 (hu)
HU (1) HUP0103452A3 (hu)
ID (1) ID27840A (hu)
IL (1) IL141030A0 (hu)
IS (1) IS5813A (hu)
MA (1) MA26675A1 (hu)
NO (1) NO20010686L (hu)
NZ (1) NZ509296A (hu)
OA (1) OA11594A (hu)
PA (1) PA8479201A1 (hu)
PE (1) PE20000951A1 (hu)
PL (1) PL346041A1 (hu)
SK (1) SK1872001A3 (hu)
SV (1) SV1999000123A (hu)
TN (1) TNSN99156A1 (hu)
TR (1) TR200100474T2 (hu)
UA (1) UA59453C2 (hu)
UY (1) UY25993A1 (hu)
WO (1) WO2000009485A1 (hu)
YU (1) YU5201A (hu)
ZA (1) ZA200101042B (hu)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
US6846799B1 (en) 1998-08-18 2005-01-25 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
WO2000012093A1 (en) * 1998-08-31 2000-03-09 Merck & Co., Inc. Method of treating neurodegenerative diseases
US6509337B1 (en) * 1998-09-17 2003-01-21 Pfizer Inc. Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
JP2001322977A (ja) * 2000-05-12 2001-11-20 Kotobuki Seiyaku Kk ピペコリン酸誘導体及びその製造方法並びにこれを含有する医薬組成物
JP2002105073A (ja) * 2000-09-27 2002-04-10 Shionogi & Co Ltd 新規マトリックスメタロプロテアーゼ阻害剤
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
BR0207209A (pt) 2001-02-14 2004-01-27 Warner Lambert Co Inibidores de metaloproteinase de matriz de pirimidina
DOP2002000333A (es) 2001-02-14 2002-09-30 Warner Lambert Co Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
PA8539501A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Compuestos triazolo como inhibidores de mmp
US6924276B2 (en) 2001-09-10 2005-08-02 Warner-Lambert Company Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
US6962922B2 (en) 2001-10-12 2005-11-08 Warner-Lambert Company Llc Alkynylated quinazoline compounds
CA2462442A1 (en) 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6894057B2 (en) 2002-03-08 2005-05-17 Warner-Lambert Company Oxo-azabicyclic compounds
EP1516872A4 (en) * 2002-06-26 2006-07-26 Carna Biosciences Inc NEW AZAZUCKER DERIVATIVE AND THIS MEDICAMENT CONTAINING ACTIVE SUBSTANCE
EP1534274A1 (en) * 2002-07-17 2005-06-01 Warner-Lambert Company LLC Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
BR0312666A (pt) * 2002-07-17 2005-05-10 Warner Lambert Co Combinação de um inibidor alcina alostérico de metaloproteinase-13 de matriz com um inibidor seletivo da cicloxigenase-2 à exceção de celecoxib e do valdecoxib
WO2004014866A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
EP1537090A1 (en) 2002-08-13 2005-06-08 Warner-Lambert Company Llc Chromone derivatives as matrix metalloproteinase inhibitors
WO2004014923A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Pyrimidinone fused bicyclic metalloproteinase inhibitors
WO2004014908A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Heterobicylcic metalloproteinase inhibitors
EP1553949B1 (en) 2002-08-13 2007-04-18 Warner-Lambert Company LLC Pyrimidine-2,4-dione derivatives as matrix metalloproteinase inhibitors
AU2003249540A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused bicyclic metalloproteinase inhibitors
WO2004014378A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc 3-isoquinolinone derivatives as matrix metalloproteinase inhiitors
AU2003253186A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Fused tetrahydropyridine derivatives as matrix metalloproteinase inhibitors
CA2494014A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
PA8578101A1 (es) 2002-08-13 2004-05-07 Warner Lambert Co Derivados de heterobiarilo como inhibidores de metaloproteinasa de la matriz
WO2006131836A2 (en) * 2005-03-22 2006-12-14 Innodia Inc. Compounds and compositions for use in the prevention and treatment of obesity and related syndromes
NZ587799A (en) 2008-03-25 2012-06-29 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
PL2243772T3 (pl) 2009-04-14 2012-05-31 Affectis Pharmaceuticals Ag Nowi antagoniści p2x7r i ich zastosowanie
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
DE202016007195U1 (de) 2016-11-16 2017-11-17 Bernhard Kohler Strombegrenzende Schalteinrichtung
US20220008401A1 (en) * 2019-01-29 2022-01-13 Darsha Llc Compositions and methods for treating pulmonary disease with matrix metalloproteinase inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2218503C (en) * 1995-04-20 2001-07-24 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
AU725831C (en) * 1995-12-08 2002-10-17 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses, and methods and intermediates useful for their preparation
RU2221782C2 (ru) * 1996-08-28 2004-01-20 Дзе Проктер Энд Гэмбл Компани Замещенные циклические аминовые ингибиторы металлопротеаз
US6303636B1 (en) * 1997-02-03 2001-10-16 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
BR9807678A (pt) * 1997-02-11 2000-02-15 Pfizer Derivados de ácidos arilsulfonil-hidroxâmicos
AU7294098A (en) * 1997-05-09 1998-11-27 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

Also Published As

Publication number Publication date
PE20000951A1 (es) 2000-09-27
US6329397B1 (en) 2001-12-11
ES2263279T3 (es) 2006-12-01
ID27840A (id) 2001-04-26
US20030008901A1 (en) 2003-01-09
GEP20033117B (en) 2003-11-25
SV1999000123A (es) 2000-07-06
HK1040242A1 (zh) 2002-05-31
KR20010085374A (ko) 2001-09-07
AU4924799A (en) 2000-03-06
AU766366B2 (en) 2003-10-16
ATE325791T1 (de) 2006-06-15
BG105323A (en) 2001-10-31
AP2001002070A0 (en) 2001-03-31
DE69931266T2 (de) 2007-02-15
EA200100126A1 (ru) 2001-08-27
PA8479201A1 (es) 2000-09-29
TR200100474T2 (tr) 2001-06-21
EE200100086A (et) 2002-08-15
CA2340202C (en) 2006-02-07
CZ2001484A3 (cs) 2002-05-15
IS5813A (is) 2001-01-16
YU5201A (sh) 2003-07-07
SK1872001A3 (en) 2002-08-06
CA2340202A1 (en) 2000-02-24
JP2002522528A (ja) 2002-07-23
TNSN99156A1 (fr) 2005-11-10
AR019241A1 (es) 2001-12-26
PL346041A1 (en) 2002-01-14
DE69931266D1 (en) 2006-06-14
EP1104403A1 (en) 2001-06-06
HN1999000131A (es) 2000-03-24
OA11594A (en) 2004-07-11
DZ2870A1 (fr) 2003-12-15
GT199900131A (es) 2001-02-02
EP1104403B1 (en) 2006-05-10
NO20010686D0 (no) 2001-02-09
ZA200101042B (en) 2002-10-07
CN1316995A (zh) 2001-10-10
WO2000009485A1 (en) 2000-02-24
HUP0103452A3 (en) 2002-10-28
MA26675A1 (fr) 2004-12-20
UY25993A1 (es) 2000-03-31
HRP20010098A2 (en) 2002-02-28
BR9912909A (pt) 2001-05-08
NZ509296A (en) 2003-10-31
IL141030A0 (en) 2002-02-10
UA59453C2 (uk) 2003-09-15
NO20010686L (no) 2001-04-09

Similar Documents

Publication Publication Date Title
HUP0103452A2 (hu) MMP inhibitor hidroxi-pipekolát-hidroxámsav származékok és a vegyületeket tartalmazó gyógyászati készítmények
HUP0301625A2 (hu) Réztartalmú amin-oxidáz inhibitor hatású 1,3,4-oxadiazin-vegyületek, eljárás az előállításukra és alkalmazásuk gyógyszerkészítmények előállítására
HUP9700992A2 (hu) 3-(Piperid-4-il)-1,2-benzizoxazol- és 3-(piperazin-4-il)-1,2-benzizoxazol-származékok, eljárás előállításukra, valamint ezeket tartalmazó gyógyászati készítmények
IL108602A0 (en) N-alkyl-2-substituted atp analogues, their preparation and pharmaceutical compositions containing them
HUP9902136A2 (hu) Szubsztituált ciklusos aminosavszármazékok, alkalmazásuk, a vegyületeket tartalmazó gyógyászati készítmények
HUP0203971A2 (hu) Imidazoimidazolok és -triazolok mint gyulladásellenes szerek és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
HUP0400699A2 (hu) Fenetanolaminszármazékok, eljárás előállításukra és ilyen vegyületeket tartalmazó gyógyszerkészítmények
HUP0102422A2 (hu) Rákellenes hatású izotiazolszármazékok, ilyen vegyületeket tartalmazó gyógyszerkészítmények és az előállítási eljárások
HUP0303084A2 (hu) Gyulladásgátló hatású 17béta-karbotioát-17alfa-arilkarboniloxiloxi androsztán-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP9702345A2 (hu) 3-Hidroxi-piridin-2-karbonsav-amid-észter-származékok, eljárás előállításukra, e vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
MY119623A (en) Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of benign prostatic hyperplasia
HUP0401638A2 (hu) Daganatellenes hatású tiofén- és tiazolszulfonamid származékok, valamint ezeket tartalmazó gyógyászati készítmények
HUP0102068A2 (hu) Módszer a prosztatarák kemoprevenciós megelőzésére
MXPA05007494A (es) Nuevos compuestos.
HUP0203524A2 (hu) Daganatellenes hatású 2- (1H-indol-3-il)-2-oxo-acetamidok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0003577A2 (hu) Tetrahidro-gamma-karbolinok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
HRP20070030T3 (en) Derivatives of benzothiazine and benzothiadiazine, procedure for their preparation and pharmaceutical compositions containing them
HUP0202433A2 (hu) NMDA receptor antagonista hatású helyettesített pirrolidin-2,3,4-trion-3-oxim-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények
HUP0103411A2 (hu) Ciklusos vegyületek, amelyeket dyslipidémia, ateroszklerózis és diabétesz kezelésére lehet használni, a vegyületeket tartalmazó gyógyászati készítmények és a vegyületek előállítására szolgáló eljárás
MXPA05000004A (es) Derivados de triazina y oxazina como inhibidores de la metaloproteasa-13 de matriz para tratar artritis.
HUP0201024A2 (hu) Izoindoloindolon-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények
HUP0004317A2 (hu) 5-HT1F agonisták
HUP9903526A2 (hu) Pirimidinszármazékok és az ezeket tartalmazó gyógyszerkészítmények
HUP0003880A2 (hu) Biciklusos heteroaril-hidroxaminsavak orto-szulfonamido-származékai, ezeket tartalmazó mátrix-metalloproteináz- és TACE-inhibitorként hatásos gyógyszerkészítmény és eljárás előállításukra
HUP0104624A2 (hu) Nukleotid szintézis-inhibítorokat tartalmazó, javított terápiás szélességű készítmény